RDHL (Redhill Biopharma) LT-Debt-to-Total-Asset : 0.01 (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Redhill Biopharma's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.01.

Redhill Biopharma's long-term debt to total assets ratio declined from Dec. 2022 (0.04) to Jun. 2024 (0.01). It may suggest that Redhill Biopharma is progressively becoming less dependent on debt to grow their business.

Redhill Biopharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Redhill Biopharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma LT-Debt-to-Total-Asset Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.47

0.48

0.04

0.02

Redhill Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.10	0.03	0.02	0.01

Redhill Biopharma LT-Debt-to-Total-Asset Calculation

Redhill Biopharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.455	/	23.047
	=	0.02

Redhill Biopharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	0.19	/	22.024
	=

Redhill Biopharma (NAS:RDHL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Redhill Biopharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.